Vaxdyn is dedicated to prevent and alleviate the effects of the global health crisis caused by superbacteria, the pathogenic bacteria developing resistance to available antibiotics.

Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators on development of multi-valent vaccines for preventing antibiotic-resistant infections in all regions of the world.

Vaxdyn’s vaccines target high-risk populations. Population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates.

Vaxdyn´s Technology

Vaxdyn was founded as a spin-off established by researchers of the Institute of Biomedicine of Seville, a center of the Andalusian Public Health System and the University of Seville linked to the University Hospital Virgen del Rocío of Seville. Decades of research on antibiotic-resistant bacteria led to AcinetoVax, a very unique vaccine candidate against multi-drug resistant Acinetobacter baumannii protected by an international patent family published as WO 2015/169809 and granted in many jurisdictions.

Immunity to combat the most worrisome superbacteria

Vaxdyn has worked on transforming AcinetoVax, a monovalent vaccine candidate, into a technological platform able to deliver multi-valent vaccines for raising immunity against several superbacteria with a single vaccine.

The first multi-valent candidate KapaVax has been designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization. 

These 3 pathogens are responsible for more than 40% of pneumonia cases that do not respond to available antibiotics. Creating immunity against these superbacteria is an urgent need for populations in the community with chronic lung disease, as those affected by chronic obstructive pulmonary disease (COPD), cystic fibrosis or primary ciliary dyskinesia. It is also an urgent need to prevent secondary infections in patients admitted to hospital with high probability of receiving mechanical ventilation, like Covid-19 affected patients, or patients admitted for certain surgical procedures or transplants.

By using the same proprietary technology Vaxdyn is widening its pipeline to deliver vaccine candidates targeting other populations in urgent need, like women with recurrent urinary-tract infections produced by antibiotic-resistant uropathogenic Escherichia coli or Klebsiella pneumoniae.

Powered by CARB-X

Vaxdyn’s candidate KapaVax is supported by the international organization headquartered in Boston CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). Vaxdyn is the first Spanish biotech to be funded by CARB-X, a global non-profit partnership investing $500 million in the development of innovative vaccines, antibiotics and rapid diagnostics to fight drug-resistant bacteria around the world.

 Founders and core management 

Vaxdyn’s management team includes members with both scientific and business expertise.

Juan José Infante
Juan José InfanteCEO, Shareholder & Chairman of the Board
Dr. Infante obtained his Ph.D. (Microbiology and Biochemistry) from the University of Cádiz, Spain and completed his academic formation with a senior researcher position in the Department of Biochemistry of the University of Washington in Seattle, USA. He joined the biotech private sector in 2007, serving as Chief Scientific Officer of Bionaturis and ADL Bionatur Solutions in Spain. Specialized in the development of biotechnological assets, covering intellectual property, R&D, and licensing, he became CEO of Vaxdyn in November 2013
Michael McConnell
Michael McConnellChief Scientific Officer Founder
Dr. McConnell is a medical doctor from the University of Michigan, biochemistry graduate from the University of Notre Dame, and Ph.D. in microbiology and Immunology from the University of Michigan. He founded Vaxdyn in 2011 while researching on vaccines and immunotherapies against antibiotic-resistant bacteria at the Institute of Biomedicine of Seville. Since 2018, Dr. McConnell is a principal investigator at the Unit of Nosocomial Infections at the Microbiology National Center (CNM) of the Institutes of Health Carlos III of Spain in Madrid. He has led more than 20 research projects in bacteriology, published more than 50 articles in peer-reviewed international journals and filed 7 patents.

He subsequently obtained his M.D. and Ph.D. in Microbiology and Immunology from the University of Michigan, United States.

He has eight years of experience in the vaccine development field. His previous work has included the development of a vaccine for rapid vaccination against anthrax at the University of Michigan Medical School.

He currently is the lead investigator in the development of a vaccine for Acinetobacter baumannii at the University Hospital Virgen del Rocío.

Pilar Pérez Romero
Pilar Pérez RomeroFounder & Advisor
Dr. Pérez-Romero is a principal investigator of Virology at the Microbiology National Center (CNM) of the Institutes of Health Carlos III of Spain in Madrid. Her work focuses on the characterization of viral infections and their immune response. She is a member of the Spanish Network for AIDS Investigation, the European Society for Clinical Microbiology and Infectious Diseases and the American Society for Virology. She was a founder of Vaxdyn while leading research in the Infectious Diseases Group at the Institute of Biomedicine of Seville. She obtained her B.S. degree in Biology and her Ph.D. in Microbiology from the University of Seville in Spain.
Astrid Pérez
Astrid PérezVaccine Candidate Optimization Leading Scientist
Dr. Pérez-Gómez is an international research reference in clinical microbiology and infectious diseases, with 50 publications cited 954 times (H index 16), 2 patents, and 30 international conferences. She has investigated the molecular basis of antimicrobial resistance and virulence factors in multi-resistant bacteria and development of bacterial vaccines. She developed her previous research work at the Institute of Biomedical Research of A Coruña, Spain and Miami University (Oxford OH, USA). She joined Vaxdyn in 2021 as leading scientist for delivering novel vaccine candidates based on Vaxdyn’s technology for further development.